i
V116: An Investigational Adult Specific Pneumococcal Conjugate Vaccine : Key Results from the Phase 3 Clinical Development Program
-
February 29, 2024
[PDF-780.34 KB]
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Subjects:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Collection(s):
-
Main Document Checksum:urn:sha256:57ad61fc3f50f37065ce7c187ba5954298b9a0529f584911effb48543c2c64d2
-
File Type:
Supporting Files
-
No Additional Files
More +
Related Documents
-
Personal Author:Self, Wesley H. ;Rouphael, Nadine...February 29, 2024 | ACIP meeting Pneumococcal VaccinesDescription:Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USAhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-...Personal Author:Das, RituparnaFebruary 29, 2024 | ACIP meeting Respiratory Syncytial Virus (RSV) Older Adults VaccineDescription:The safety and efficacy of this investigational RSV vaccine have not been established in any country for any use02-RSV-Adults-Das-508.pdf
More +
You May Also Like
Checkout today's featured content at stacks.cdc.gov